Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Volume is low

<< Previous

Bullboard Posts

Next >>

Post by Doccoleon Jul 13, 2022 10:54am

124 Views

Post# 34820692

Volume is low

I wouldn't be surprised if there is more selling. John has so many shares, and our volume is generally so low, it could take over a month to sell all his shares.

I would be cautious here. If you are a new investor, I would wait, there will be time in the future to jump on if it ever gets there.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec